Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous AGX-201 for Migraine Prophylaxis
NCT02021474Phase 2Unknown
- Sponsor
- AgoneX Biopharmaceuticals, Inc.
- Start
- Oct 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of histamine in migraine (2 arms), sponsored by AgoneX Biopharmaceuticals, Inc. Primary endpoint: Mean change from baseline in monthly migraine days. Status: unknown.
02
Drugs
histamine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02021474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021474.